Drug Trial Radar · NCT04005352
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
734
Actual
Start
Sep 25, 2019
Primary completion
Sep 9, 2022
Study completion Sep 9, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.
Conditions
- Age-related Macular Degeneration
Interventions
Brolucizumab 6 mgBiological
Intra-vitreal injection
Aflibercept 2 mgBiological
Intra-vitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Distribution of the Last Interval With no Disease Activity up to Week 32 - Study EyeTime frame: Up to Week 32
- Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study EyeTime frame: Baseline, Week 28 and Week 32
Locations
118 sites in 20 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Huntington Beach, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Pinellas Park, Florida
Novartis Investigative Site
Winter Haven, Florida
Novartis Investigative Site
Springfield, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
West Des Moines, Iowa
Novartis Investigative Site
Minneapolis, Minnesota
Novartis Investigative Site
Hickory, North Carolina
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Springfield, Oregon
Novartis Investigative Site
Germantown, Tennessee
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Bellaire, Texas
Novartis Investigative Site
Fort Worth, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, De Santa Fe, Argentina
Novartis Investigative Site
Albury, New South Wales, Australia
Novartis Investigative Site
Hurstville, New South Wales, Australia
Novartis Investigative Site
Parramatta, New South Wales, Australia
Novartis Investigative Site
Sydney, New South Wales, Australia
Novartis Investigative Site
Southport, Queensland, Australia
Novartis Investigative Site
Glen Waverley, Victoria, Australia
Novartis Investigative Site
Rowville, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Alken, Belgium
Novartis Investigative Site
Leuven, Belgium
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.